Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jid.2023.01.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Divergent on-target off-tumor effects by CAR T and CAR NK cells suggest different efficacy and safety of cell therapies.
Oncoimmunology
December 2025
Department for Cell and Gene Therapy Development, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany.
CAR-based cell therapies have shown clinical success in treating various cancers, with CAR T cell therapies entering the clinical route and CAR NK cell therapies being evaluated in early-stage clinical trials. A key challenge is the presence of tumor-associated antigens on healthy cells, risking on-target off-tumor toxicities. Our comparative analysis of CAR T and CAR NK cells targeting the multiple myeloma-associated antigens BCMA, SLAMF7, and CD38 revealed that antigen density on target cells significantly modulates CAR NK cell activation and cytotoxicity.
View Article and Find Full Text PDFCoronary artery disease (CAD), tuberculosis (TB), and HIV represent major global health burdens. Individuals affected by one or more of these conditions often exhibit chronic inflammation and immune dysregulation, with monocytes playing a central role in these processes. Monocyte subsets are known to expand in individuals with HIV, TB, or CAD.
View Article and Find Full Text PDF[Future directions in the management of warm autoimmune hemolytic anemia].
Rinsho Ketsueki
September 2025
Department of Hematology, Kawasaki Medical School.
Warm autoimmune hemolytic anemia (wAIHA) is an autoimmune disorder in which autoantibodies target the patient's own red blood cells. It can be classified as either idiopathic (primary) or secondary and is characterized by the presence of pan-reactive immunoglobulin G (IgG) autoantibodies that recognize epitopes on erythrocyte membrane proteins such as band 3 and Rh polypeptides. Spontaneous remission is rare, and corticosteroids are commonly used as first-line therapy.
View Article and Find Full Text PDFThe Role of CELMoD Agents in Multiple Myeloma.
Onco Targets Ther
August 2025
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Although recent decades have seen continued improvements in survival for patients with multiple myeloma, the disease remains largely incurable, and most patients will experience relapse and/or become refractory to treatment. There thus remains an urgent unmet need for novel treatments, particularly for those patients with relapsed or refractory multiple myeloma. Novel treatment modalities, such as targeted protein degradation, have attracted particular interest due to their ability to expand the range of druggable protein targets in myeloma cells.
View Article and Find Full Text PDF